Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06683352 | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People | PHASE1 | COMPLETED | 1,353 | — | — | Nov 11, 2024 | Jul 15, 2025 | Aug 15, 2025 | 22 | United States |
Describe prompted local reactions following investigational product administration
Describe prompted systemic events following investigational product administration
Describe AEs occurring through 4 weeks following administration of investigational product
Describe SAEs through 6 months following administration of investigational product
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | COVID-19 Vaccine (Dose 1) and Placebo |
| Arm B | EXPERIMENTAL | COVID-19 Vaccine (Dose 2) and Placebo |
| Arm C | ACTIVE_COMPARATOR | COVID-19 Vaccine (Dose 3) and Placebo |
| Arm D | EXPERIMENTAL | Investigational Influenza Vaccine (Dose 1) and Placebo |
| Arm E | ACTIVE_COMPARATOR | Licensed Influenza Vaccine 1 and COVID-19 Vaccine (Dose 3) |
| Arm EE | ACTIVE_COMPARATOR | Licensed Influenza Vaccine 2 and COVID-19 Vaccine (Dose 3) |
| Arm F | EXPERIMENTAL | Investigational Influenza Vaccine (Dose 2) and Placebo |
| Arm G | EXPERIMENTAL | Influenza and COVID Combination Vaccine (Combination 1) and Placebo |
| Arm H | EXPERIMENTAL | Influenza and COVID Combination Vaccine (Combination 2) and Placebo |
| Arm I | EXPERIMENTAL | Influenza and COVID Combination Vaccine (Combination 3) and Placebo |
| Arm J | EXPERIMENTAL | Investigational Influenza Vaccine (Dose 3) and Placebo |
| Arm K | EXPERIMENTAL | Influenza and COVID Combination Vaccine (Combination 4) and Placebo |
| Arm L | EXPERIMENTAL | Influenza and COVID Combination Vaccine (Combination 5) and Placebo |
| Arm M | EXPERIMENTAL | Influenza and COVID Combination Vaccine (Combination 6) and Placebo |
| Arm N | EXPERIMENTAL | Influenza and COVID Combination Vaccine (Combination 7) and Placebo |
| Name | Type | Description |
|---|---|---|
| Investigational Influenza Vaccine | BIOLOGICAL | Investigational Influenza Vaccine |
| COVID-19 Vaccine | BIOLOGICAL | Pfizer-BioNTech COVID-19 Vaccine |
| Influenza and COVID Combination Vaccine | COMBINATION_PRODUCT | Combined investigational influenza and Pfizer-BioNTech COVID-19 Vaccine |
| Licensed Influenza Vaccine 1 | BIOLOGICAL | Licensed Influenza Vaccine 1 |
| Licensed Influenza Vaccine 2 | BIOLOGICAL | Licensed Influenza Vaccine 2 |
| Placebo | OTHER | Saline |
Inclusion Criteria: * Participants 18 years of age or older * Healthy participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study. Exclusion Criteria: * Vaccination with any ...